<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590873</url>
  </required_header>
  <id_info>
    <org_study_id>2018-051</org_study_id>
    <nct_id>NCT03590873</nct_id>
  </id_info>
  <brief_title>The Effect of Restrictive Fluid and Vasopressin During Surgery of Burn Patients</brief_title>
  <official_title>The Effect of Restrictive Fluid and Vasopressin During Surgery of Burn Patients: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangang Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangang Sacred Heart Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blinded study to investigate in which the groups are designated
      as the control group and the restrictive group to further evaluate significant differences in
      intraoperative blood loos during burn surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blinded study to investigate the effect of fluid restriction and
      vasopressin on blood loss during surgery of the burn patients. The groups are designated as
      the control group and the restrictive group to further evaluate significant differences in
      intraoperative blood loss during the surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">June 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>At the end of the surgery, approximately 3 hrs</time_frame>
    <description>Comparison of the amounts of estimated blood loss in the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative red blood cell transfusion</measure>
    <time_frame>At the end of the surgery, approximately 3 hrs</time_frame>
    <description>Comparison of total units of red blood cell transfusion in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pulmonary complication</measure>
    <time_frame>Within 7 postoperative days</time_frame>
    <description>Comparison of postoperative pulmonary complication in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative cardiovascular complication</measure>
    <time_frame>Within 7 postoperative days</time_frame>
    <description>Comparison of postoperative cardiovascular complication in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative renal complication</measure>
    <time_frame>Within 7 postoperative days</time_frame>
    <description>Comparison of postoperative acute kidney injury in the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Burn Surgery</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.
Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.</description>
    <arm_group_label>Restrictive group</arm_group_label>
    <other_name>Antidiuretic hormone, arginine vasopressin, or argipressin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  age â‰¥ 18 years old

          -  burn patients undergoing surgery (TBSA &gt; 20%)

        Exclusion criteria:

          -  age &lt; 18 years old

          -  history of renal disorder

          -  history of cardiac disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Kug Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee Yeong Kim, MD</last_name>
    <phone>82226395650</phone>
    <email>kimhy@hallym.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hangang Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Yeong Kim, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 29, 2018</last_update_submitted>
  <last_update_submitted_qc>July 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hangang Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Hee Yeong Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

